1. Home
  2. GLUE

as 09-18-2025 3:18pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Founded: 2019 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 308.8M IPO Year: 2021
Target Price: $13.50 AVG Volume (30 days): 2.1M
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.29 EPS Growth: N/A
52 Week Low/High: $3.50 - $12.40 Next Earning Date: 11-06-2025
Revenue: $177,986,000 Revenue Growth: 2990.57%
Revenue Growth (this year): 83.76% Revenue Growth (next year): -61.27%

GLUE Daily Stock ML Predictions

Share on Social Networks: